TrialJAMA oncology2018

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.

Susan M O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.